Review article: The management of mild to severe acute ulcerative colitis

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 4, 2004, Pages 88-92

  Travis, S P L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BALSALAZIDE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; EPIDERMAL GROWTH FACTOR; HEPARIN; HYDROCORTISONE; INFUSION FLUID; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; OLSALAZINE; PREDNISOLONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANEMIA; ANTIBIOTIC THERAPY; BLOOD TRANSFUSION; CLINICAL TRIAL; COLON DILATATION; COLON RESECTION; CORTICOSTEROID THERAPY; DEHYDRATION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; ERYTHROCYTE SEDIMENTATION RATE; FEVER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERMAGNESEMIA; INTRAVENOUS ADMINISTRATION; LEUKAPHERESIS; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MELENA; MONOTHERAPY; NUTRITIONAL SUPPORT; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; TACHYCARDIA; THROMBOEMBOLISM; ULCERATIVE COLITIS; UNITED KINGDOM;

ACUTE DISEASE; COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; TREATMENT OUTCOME;

EID: 4844230146     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Hardy TL, Bulmer E. Ulcerative colitis: survey of 95 cases. Br Med J 1933; ii: 812-5.
2. Rice-Oxley JM, Truelove SC. Ulcerative colitis: course and prognosis. Lancet 1950; i: 663-6.
3. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955; ii: 1041-8.
4. Hawthorne AB, Travis SPL and the BSG IBD Clinical Trials Network. Outcome of inpatient management of severe ulcerative colitis: a BSG IBD Clinical Trials Network Survey. Gut 2002; 50: A16(Abstract).
5. Stenner JMC, White P, Gould SR, Lim AG. Audit of the management of severe ulcerative colitis in a DGH. Gut 2001; 48: A87(Abstract).
6. Irvine EJ. Assessing outcomes in clinical trials. In: Satsangi J, Sutherland LR, eds. Inflammatory Bowel Diseases. London: Churchill Livingstone, 2003: 319-33.
7. Walmsley RS, Ayres RCS, Pounder RE, Allan RN. A simple clinical colitis index. Gut 1998; 43: 29-32.
8. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987; 317: 1625.
9. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev 2000; 2: CD000543.
10. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-71.
11. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263-76.
12. Gionchetti P, Rizzello F, Venturi A, et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther 1997; 11: 1053-7.
13. Marshal JK, Irvine EJ. Rectal corticosteroids versus alternative treatment in ulcerative colitis: a meta-analysis. Gut 1997; 40: 775-81.
14. Sinha A, Nightingale JMD, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided colitis or proctitis. N Engl J Med 2003; 349: 350-7.
15. Travis SPL, RDP Investigators' Study Group, Yap L, et al. RDP58 - a novel and effective oral therapy for ulcerative colitis (UC): results of parallel prospective, multicentre, blinded, placebo-controlled trials. Gut 2003; 52(Suppl. VI): A5.
16. Hanai H, Watanabe F, Takeuchi K, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled pilot study. Clin Gastroenterol Hepatol 2003; 1: 28-35.
17. Daperno M, Sostegni R, Rocca R, et al. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 7-12.
18. Truelove SC, Jewell DP. Intensive treatment regimen for severe attacks of ulcerative colitis. Lancet 1974; i: 1067-70.
19. Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993; 88: 227-32.
20. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Gut 1986; 27: 1210-2.
21. Mantazaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89: 43-6.
22. D'Haens G, Lemmens L, Geboes K, et al. Intravenous ciclosporin versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-9.
23. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous ciclosporin in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-31.
24. Travis SPL, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
25. Gelbmann CM. Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease - do we have reliable markers? Inflamm Bowel Dis 2000; 6: 123-31.
26. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-5.
27. Hawthorne AB. Ciclosporin and refractory colitis. Eur J Gastroenterol Hepatol 2003; 15: 239-44.
28. Actis GC, Aimo G, Priolo G, et al. Efficacy and efficiency of oral microemulsion ciclosporin versus intravenous and soft gelatin capsule ciclosporin in the treatment of severe, steroid refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998; 4: 276-9.